Oglufanide
Also known as: gamma-D-glutamyl-L-tryptophan, Oglufanide disodium, SCV-07
Source Oglufanide at Peptiology
Save 10% with code PEPTI-BOSSRABBIT-10
Tapping Shop Now & Save 10% copies your 10% off code PEPTI-BOSSRABBIT-10 to your clipboard. Paste it at the Peptiology checkout to claim the discount.
Summary
Oglufanide (SCV-07, gamma-D-glutamyl-L-tryptophan) is a synthetic immunomodulatory dipeptide investigated primarily for its ability to restore immune function in chronic viral infections, particularly hepatitis C, and for oral mucositis associated with radiation therapy. It has shown activity in stimulating T-cell responses and has been studied in Russian clinical contexts as well as Western investigational trials.
Mechanism of Action
Synthetic dipeptide (gamma-D-glutamyl-L-tryptophan) that modulates immune function by activating T-lymphocytes and natural killer cells, enhancing cytokine production (including IL-2 and interferon-gamma), and restoring immune homeostasis in immunocompromised states.
Routes of Administration
Goals & Uses
- Immunorestoration in immunodeficiencyImmunologyLow
- Hepatitis C immune modulationInfectious DiseaseModerate
- Tuberculosis adjunct therapyInfectious DiseaseLow
- Treatment of oral mucositis from radiationOncology Supportive CareModerate
Contraindications
- Organ transplant recipients on immunosuppressionTransplantModerate
- Active autoimmune diseaseAutoimmunityModerate
- Known hypersensitivity to oglufanide or its componentsAllergyHigh
Adverse Effects
- Injection site reactionsLocalCommon
- NauseaGastrointestinalUncommonFeeling of sickness or urge to vomit
- FatigueGeneralUncommonLow energy or tiredness
- Fever/flu-like symptomsSystemicUncommon
Drug Interactions
- Interferons (e.g., pegylated interferon-alpha)Low
- Immunosuppressants (e.g., corticosteroids, cyclosporine)Moderate
Population Constraints
- PregnancyReproductive SafetyRelative
- Severe hepatic or renal impairmentOrgan ImpairmentRelative
- Pediatric patientsAgeRelative
Regulatory Status
- European UnionUnknownNo EMA approval; limited regulatory history in EU.
- United StatesInvestigationalStudied under IND for oral mucositis and hepatitis C; no FDA approval.
- United KingdomUnknownNo MHRA approval documented.
Not approved by the FDA or EMA. Investigated under IND in the US for oral mucositis and hepatitis C. Has been used in some Eastern European countries under research or compassionate-use frameworks. No current approved indication in major Western regulatory jurisdictions.
Evidence & Sources
No sources recorded yet.
Frequently Asked Questions
What is Oglufanide?
Oglufanide (SCV-07, gamma-D-glutamyl-L-tryptophan) is a synthetic immunomodulatory dipeptide investigated primarily for its ability to restore immune function in chronic viral infections, particularly hepatitis C, and for oral mucositis associated with radiation therapy. It has shown activity in stimulating T-cell responses and has been studied in Russian clinical contexts as well as Western investigational trials.
What is Oglufanide used for?
Oglufanide is educationally associated with: Immunorestoration in immunodeficiency, Hepatitis C immune modulation, Tuberculosis adjunct therapy, Treatment of oral mucositis from radiation. Educational only — not medical advice.
How is Oglufanide administered?
Recorded routes of administration: Oral, Subcutaneous.
What are the potential side effects of Oglufanide?
Reported adverse effects include: Injection site reactions, Nausea, Fatigue, Fever/flu-like symptoms. This list is not exhaustive — consult a qualified clinician.
Who should avoid Oglufanide?
Recorded contraindications: Organ transplant recipients on immunosuppression, Active autoimmune disease, Known hypersensitivity to oglufanide or its components. Consult a qualified clinician before use.